CSD/BSE&NSE/PR/2026-2027
Date: November 26, 2026

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company titled "**Suven Life Sciences Announces First Patient Randomized in Global Phase-3 AWAKE Study of Samelisant for Narcolepsy"**

This is for your information and record.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

Kandari Sangeetha Laxmi
Digitally signed by Kandari Sangeetha Laxmi
Date: 2026.11.26 11:52:08 +05'30'

K. Sangeetha Laxmi
Company Secretary

Encl.: as above

News Release

Suven Life Sciences Announces First Patient Randomized in Global Phase-3 AWAKE Study of Samelisant for Narcolepsy.

- *First Patient Randomized at a clinical site in the USA.*
- *Global Phase-3 being conducted across North America (USA & Canada); Europe (Italy, France, Germany, Spain).*
- Samelisant is being developed for both Narcolepsy Type-1 (NT1) and Narcolepsy Type-2 (NT2).

Hyderabad, India, 26-Nov-2026: Suven Life Sciences Ltd. (Suven), a clinical-stage biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders, today announced the *Randomization of the First Patient* in its Phase-3 AWAKE clinical study evaluating Samelisant for the treatment of Excessive Daytime Sleepiness (EDS) in patients with Narcolepsy (ClinicalTrials.gov ID: NCT07540364).

The randomization of the first patient at a clinical study site in the United States marks an important milestone in the clinical development of Samelisant.

Samelisant:

Samelisant (SUVN-G3031) is a novel, potent and selective histamine H3 receptor inverse agonist being developed for the treatment of narcolepsy. By enhancing histaminergic neurotransmission, Samelisant is designed to promote wakefulness and improve daytime functioning.

Samelisant is being developed for both Narcolepsy Type-1 (NT1) and Narcolepsy Type-2 (NT2), potentially offering a treatment approach across the two major forms of narcolepsy. While NT1 is characterized by orexin deficiency and cataplexy, NT2 is primarily characterized by excessive daytime sleepiness without cataplexy. The potential applicability of Samelisant across both patient populations represents an important aspect of its clinical development.

Its distinct pharmacological profile, non-scheduled status, favorable safety profile and potential to alleviate excessive daytime sleepiness through modulation of the histaminergic system position Samelisant as a promising therapeutic candidate. With encouraging Phase-2 clinical findings and ongoing Phase-3 evaluation, Samelisant has the potential to emerge as a best-in-class treatment option for patients with narcolepsy.

Global Phase-3 AWAKE Study Design:

The Phase-3 AWAKE study is a randomized, double-blind, placebo-controlled, multicenter clinical trial being conducted across North America (USA & Canada) and Europe (Italy, France, Germany, Spain). The study plans to enroll approximately 240 adult patients diagnosed with NT1 or NT2.

Eligible participants are randomized to receive Samelisant or placebo. The study comprises a 4-week screening period, followed by a 12-week treatment period and a subsequent safety follow-up period. Enrollment of the last participant is anticipated by Dec-2027, with topline study results expected in the H1-2028.

The primary objective is to evaluate the efficacy of Samelisant in improving excessive daytime sleepiness, measured using the Epworth Sleepiness Scale (ESS). Objective wakefulness, assessed through the Maintenance of Wakefulness Test (MWT), along with other clinically relevant measures of narcolepsy symptoms, patient-reported outcomes such as weekly cataplexy rate, attention, vigilance, cognitive and functional outcomes will provide additional assessments of treatment benefit. The safety and tolerability of Samelisant will also be evaluated.

Addressing Unmet Medical Need in Narcolepsy:

Despite the availability of several approved treatments, significant unmet medical need remain in the management of narcolepsy, as some patients continue to experience residual symptoms or require individualized treatment approaches. Treatment selection can be influenced by side effect profiles, tolerability, drug interactions, dosing requirements, and controlled-substance considerations.

Samelisant offers an opportunity to advance histaminergic modulation as a therapeutic strategy for narcolepsy. H3 receptor inverse agonism is an established mechanism with demonstrated clinical efficacy, providing a strong scientific rationale for the development of Samelisant. With the potential to address limitations associated with other narcolepsy medications, including drug–drug interaction liability, and supported by a favourable safety profile, Samelisant may offer a differentiated therapeutic option. Its potential utility across both narcolepsy Type-1 (NT1) and Type-2 (NT2), together with its distinct clinical and pharmacological profile, could provide an important additional treatment option for patients with narcolepsy.

The ongoing Phase-3 AWAKE study will further characterize the efficacy and safety of Samelisant and establish its potential clinical value in the treatment of narcolepsy.

Commenting on the milestone, Mr. Venkat Jasti, Chairman and Managing Director, Suven Life Sciences, said: "*The randomization of the first patient in the Phase-3 AWAKE study marks an important milestone for Suven and reflects our continued commitment to advancing innovative therapies for patients with central nervous system disorders. Narcolepsy remains an area of*

significant unmet medical need despite the availability of several treatment options. We believe Samelisant has the potential to make a meaningful contribution to the treatment landscape through its differentiated pharmacological profile and potential applicability to both Narcolepsy Type-1 and Type-2. With the encouraging clinical findings observed to date, we are excited about advancing this program and exploring its potential to become a best-in-class treatment option for patients with narcolepsy."

"*Samelisant is being developed based on a well-established and clinically validated therapeutic mechanism involving histaminergic modulation through H3 receptor inverse agonism. Histamine plays a critical role in the regulation of wakefulness, and modulation of this pathway has demonstrated clinical efficacy in narcolepsy. The encouraging Phase-2 findings with Samelisant provide a strong rationale for its continued clinical development. The Phase-3 AWAKE study is designed to comprehensively evaluate its efficacy and safety in patients with both Narcolepsy Type-1 and Type-2, with particular emphasis on improvements in excessive daytime sleepiness. We believe Samelisant has the potential to offer an important additional treatment option for patients living with this chronic and debilitating disorder*" said Ramakrishna Nirogi, President and Chief Scientific Officer, Suven Life Sciences.

Samelisant – Key Research Publications:

- Samelisant (SUVN-G3031), a histamine 3 receptor inverse agonist: Results from the phase 2 double-blind randomized placebo-controlled study for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. ***Sleep Med. 2025; 124:618-626.***
- Samelisant (SUVN-G3031), a Potent, Selective and Orally Active Histamine H3 Receptor Inverse Agonist for the Potential Treatment of Narcolepsy: Pharmacological and Neurochemical Characterisation. ***Psychopharmacology (Berl). 2021; 238(6):1495-1511***.
- Histamine 3 Receptor Inverse Agonist Samelisant (SUVN-G3031): Pharmacological Characterization of an Investigational Agent for the Treatment of Cognitive Disorders. ***J Psychopharmacol. 2021; 35(6):713-729***.
- Absorption, Distribution, Metabolism, Excretion (ADME), Drug-drug Interaction Potential and Prediction of Human Pharmacokinetics of SUVN-G3031, a Novel Histamine 3 Receptor (H3R) Inverse Agonist in Clinical Development for the Treatment of Narcolepsy. ***Eur J Pharm Sci. 2020; 152:105425.***
- LC-MS/MS Method for the Quantification of SUVN-G3031, a Novel H3 Receptor Inverse Agonist for Narcolepsy Treatment. ***Bioanalysis 2020; 12:533-544.***
- Safety, Tolerability, and Pharmacokinetics of SUVN-G3031, a Novel Histamine-3 Receptor Inverse Agonist for the Treatment of Narcolepsy, in Healthy Human Subjects Following Single and Multiple Oral Doses. ***Clin Drug Investig. 2020; 40:603-615.***
- Discovery and Development of N-[4-(1-Cyclobutylpiperidin-4-yloxy)phenyl]-2-(morpholin-4-yl)acetamide Dihydrochloride (SUVN-G3031): A Novel, Potent, Selective, and Orally Active Histamine H3 Receptor Inverse Agonist with Robust Wake-Promoting Activity. ***J Med Chem. 2019; 62:1203-1217.***

About Suven Life Sciences:

Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in CNS disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal

disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Global Phase-3 study ongoing, enrollment completed); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase-2 study for EDS completed; pivotal Phase-3 AWAKE study for EDS is ongoing and Phase-2 study for Cataplexy is in planning); Ropanicant (SUVN-911) for MDD (Phase-2 study completed and Phase-3 study is in planning); Usmarapride (SUVN-D4010) for cognitive disorders (Phase-2 study in planning), Tenaclidine (SUVN-I6107) for cognitive disorders (Phase-1 study is completed; additional non clinical safety studies are in progress). In addition to these clinical assets, seven projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major world markets.

For more information, please visit our website http://www.suven.com.

Risk Statement: *Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.*